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Abstract 
Background/Objective: Intravenous nicardipine infusion is effective for rapid blood pressure control. However, its 
use requires hemodynamic monitoring in the intensive care unit (ICU) and is associated with high hospital cost. This 
study aimed to examine the effect of early versus late initiation of oral antihypertensives on ICU length of stay (LOS) 
and cost of hospitalization in patients with hypertensive intracerebral hemorrhage (ICH).
Methods: This is a single‑center retrospective study of patients with hypertensive ICH treated with nicardipine infu‑
sion from January 1, 2013, to December 31, 2017. Patients were dichotomized into study and control groups, based 
on receiving oral antihypertensives within 24 h versus after 24 h of emergency department arrival. Baseline character‑
istics, duration of nicardipine infusion, LOS in the ICU and hospital, functional outcome at discharge, and hospital cost 
were compared between the two groups using univariate and multivariate analysis.
Results: A total of 90 patients in the study group and 76 in the control group were identified. There was no significant 
difference in demographics, past medical history, and initial SBP between the two groups. After adjusting for confound‑
ing factors with multivariate regression models, early initiation of oral antihypertensives was associated with significant 
reductions in duration of nicardipine infusion (55.5 ± 60.1 vs 121.6 ± 141.3 h, p <0.005), nicardipine cost ($14,207 vs 
$29,299, p < 0.01), ICU LOS (2 vs 5 days, p < 0.005), and cost of hospitalization ($24,564 vs $47,366, p < 0.01). There was no 
significant difference in adversary renal events, favorable outcomes, and mortality between the two groups.
Conclusions: Early initiation of oral antihypertensives is safe and may have a significant financial impact on patients 
with hypertensive ICH.
Keywords: Intracerebral hemorrhage, Hypertension, Nicardipine, Length of stay, Cost, Functional outcome
higher rate in developing countries [1–3]. It portends 
a high mortality rate and imposes significant financial 
stress on the patient and family. The mean hospital cost 
for patients with ICH increased from $18,300 to $28,800 
between 1990 and 2001 [4]. The hospital cost contin-
ues to rise in recent years [5]. It is therefore imperative 
to investigate cost reduction strategies for patients with 
ICH.
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Introduction
Spontaneous intracerebral hemorrhage (ICH) is one of 
the most devastating types of stroke, with an incidence 
of about 10 per 100,000 person-years in the USA and a 
Hypertension is the most common risk factor for spon-
taneous ICH [6, 7]. Uncontrolled hypertension is an 
independent predictor of hematoma expansion, brain 
edema, neurological deterioration, longer length of stay 
(LOS) in the intensive care unit (ICU) and hospital, and 
cost of hospitalization [8–11]. Intravenous (IV) nicardi-
pine infusion has been shown to be safe and effective for 
rapid lowering of systolic blood pressure (SBP) to less 
than 140 mmHg [9, 10, 12, 13]. Although IV nicardipine 
can be administered in a stroke unit that is staffed with 
experienced nurses 24/7, it usually requires close hemo-
dynamic monitoring in the ICU and is associated with 
high cost [14]. During an internal resource utilization 
analysis at our medical center, IV nicardipine was identi-
fied as one of the costliest drugs used in the neurological 
ICU. In addition, our previous study showed that resist-
ant hypertension in patients with ICH is associated with 
more medical interventions and longer LOS [10]. We 
therefore hypothesized that early initiation of oral anti-
hypertensives may reduce the use of intravenous nicardi-
pine infusion, ICU LOS, and cost of hospitalization. The 
aim of this study was to investigate whether early initia-
tion of oral antihypertensives is cost-effective for patients 
with hypertensive ICH.
Methods
Patients Selection
This is a retrospective study of all consecutive patients 
with spontaneous hypertensive ICH hospitalized at Uni-
versity of California Irvine Medical Center between Janu-
ary 1, 2013, and December 31, 2017. Patients with ICH 
secondary to arteriovenous malformation, ruptured 
aneurysm, tumor, trauma, cerebral amyloid angiopathy, 
and coagulopathy were excluded. In addition, patients 
with do-not-intubate (DNI)/do-not-resuscitate (DNR) 
orders within 72 h of admission, initial SBP < 180 mmHg, 
or duration of nicardipine infusion < 2  h were also 
excluded. Eligible patients were divided into study and 
control groups based on the timing of receiving oral 
antihypertensives within or after 24  h of emergency 
department (ED) arrival. The patient list was obtained 
by searching the prospectively maintained stroke center 
data for American Heart Association-Get With-The 
Guidelines-Stroke Registry.
Study Design and Protocol
In 2013 and 2014, the initiation and titration of oral anti-
hypertensives were at the discretion of Neuro ICU team. 
In January 2015, we implemented an ICU protocol for 
early initiation of oral antihypertensives on day 1 and 
rapid titrations in the next 5  days as described in our 
previous study [10]. This titration protocol led to early 
transition from iv nicardipine to oral antihypertensives. 
However, 12.2% (11/90) patients admitted between 2015 
and 2017 did not receive oral antihypertensives within 
24 h of ED arrival due to dysphagia and delayed feeding 
tube placement. We therefore defined control and study 
groups based on the timing of receiving oral antihyper-
tensives within or after 24 h of ED arrival. The study was 
approved by the Institutional Review Board of the Uni-
versity of California, Irvine.
Data on demographics (age, sex, and race), past medi-
cal history, initial highest SBP in ED, National Institutes 
of Health Stroke Scale (NIHSS) score, Glasgow Coma 
Scale (GCS) score, ICH features, mechanical ventilation, 
duration of nicardipine infusion and cost, timing of oral 
antihypertensives, creatinine levels at admission, peak 
and discharge, LOS in the ICU and the hospital, total 
cost of hospitalization, and modified Rankin Scale (mRS) 
score at discharge were collected.
The cost data were provided by the Department of 
Decision Support. Nicardipine infusion cost includes 
drug acquisition expenses and indirect cost associated 
with monitored drug infusion (preparation, administra-
tion, and ICU monitoring). The cost of hospitalization 
includes expenses incurred by the hospital in providing 
patient care, such as nursing, room and board, medi-
cines and supplies, as well as, indirect costs such as over-
head for administrative expenses including complying 
with federal and state regulatory requirements, infec-
tion control, medical records, building maintenance, and 
equipment.
The ICH score was estimated as previously described 
[15]. ICH location was classified as deep (basal ganglia or 
thalamus), lobar, brain stem, or cerebellar [10, 16]. The 
outcome at hospital discharge was divided into favora-
ble outcomes (mRS scores 0–2), unfavorable functional 
recovery (mRS scores 3–5), and death (mRS 6).
Initiation and Titration of Oral Antihypertensives
Our SBP goal for patients with hypertensive ICH was 
< 140  mmHg throughout the entire study period based 
on the results of Interact and Interact 2 trial [12, 17]. 
Patients with SBP > 140  mmHg were initially treated 
with labetalol or hydralazine 10  mg IV pro re nata and 
IV nicardipine infusion at 2.5–15 mg/h rate as described 
previously [10]. The IV nicardipine was then transitioned 
to oral antihypertensives gradually. The commonly used 
oral antihypertensives were calcium channel blocker 
amlodipine, angiotensin-converting enzyme inhibitor 
lisinopril or benazepril, angiotensin II receptor blocker 
losartan, diuretics spironolactone, β-blocker metoprolol, 
α/β-blocker labetalol or carvedilol, central α agonist clo-
nidine, and vasodilator hydralazine. Hydrochlorothiazide 
was rarely used for patients for hypertensive ICH due to 
risk of hyponatremia and worsening cerebral edema.
Statistical Analysis
Continuous variables were described by mean ± stand-
ard deviation (SD) or median with interquartile range 
(IQR) based on the results of normality testing. Categori-
cal variables were expressed by counts with percentages. 
Baseline characteristics, duration and cost of nicardi-
pine infusion, and outcomes at discharge were compared 
between study and control groups by student t or Wil-
coxon rank-sum test for continuous variables and Chi-
square test for categorical variables.
To investigate the independent effect of early initiation 
of oral antihypertensives, we first performed univari-
ate analyses to detect possible effect of early versus late 
oral antihypertensives on duration of nicardipine infu-
sion, nicardipine cost, renal function, ventilation support, 
LOS in the ICU and hospital, outcomes, numbers of oral 
antihypertensives at discharge, and cost of hospitaliza-
tion. Then, we conducted multivariate logistic regression 
models to determine which variables were independently 
associated with early initiation of oral antihypertensives 
after adjustment for initial SBP, NIHSS, GCS, and ICH 
scores.
Sensitivity analysis was further performed by dividing 
patients by admission time into control (prior to January 
2015) and study (after January 2015) groups to evaluate 
the effect of early oral antihypertensive protocol on dura-
tion of IV nicardipine infusion, hospital cost, and func-
tional outcomes of the patients with ICH.
Statistical analyses were performed using SPSS soft-
ware (version 23.0). A two-tailed value of p < 0.05 was 
considered statistically significant.
Results
A total of 604 patients with spontaneous ICH were 
admitted to our medical center during the study period. 
As shown in Fig. 1, 438 patients were excluded from the 
study (160 ICH from non-hypertensive etiology, 45 DNR/
DNI within 72 h, 226 initial SBP < 180 mmHg, 2 nicardi-
pine duration < 2  h, 5 no IV nicardipine use). Only 166 
patients with hypertensive ICH and IV nicardipine use 
for more than 2  h were included in the analysis. All 90 
patients in study group received one or two oral antihy-
pertensives within 24 h of ED arrival. Of the 76 patients 
in control group, 50 (66%), 14 (18%), and 6 (8%) received 
oral antihypertensives on day 2, 3, or 4, respectively. Oral 
antihypertensives were initiated in 6 patients (8%) on day 
5 or later.
The characteristics of patients with early versus late 
initiation of oral antihypertensives are summarized in 
Table  1. There was no significant difference in demo-
graphics, race, past medical history, and initial SBP 
between the 2 groups. Compared with control group, 
patients in study group had lower median NIHSS score 
(7.5 vs 15.5, p < 0.001) and ICH score (1 vs 1.5, p < 0.001) 
but higher GCS score (15 vs 13, p < 0.001), sugges-
tive of less severe ICH. In contrast, there was a signifi-
cantly higher proportion of dysphagia and feeding tube 
placement in control group (56.6% vs 28.9%, p < 0.001), 
which may have caused the delay in initiation of oral 
antihypertensives.
Fig. 1 Study screening flow chart
Table 1 Demographics and clinical features of study and control groups
Statistically significant values are given in bold
Variables are presented as n (%) in nominal data; mean ± SD or median (IQR) in continuous data
ED emergency department, GCS Glasgow coma scale, HTN hypertension, ICH intracerebral hemorrhage, IQR interquartile range, NIHSS National Institutes of Health 
Stroke Scale, PMH past medical history, SBP systolic blood pressure
Characteristics Study group (n = 90) Control group (n = 76) p value
Age 64.3 ± 15.4 62.8 ± 13.4) 0.067
Male 48 (53.3) 38 (50.0) 0.668
Race 0.942
 White 35 (38.9) 30 (39.5)
 Hispanic 29 (32.2) 27 (35.5)
 African‑American 6 (6.7) 4 (5.3)
 Asian 20 (22.2) 15 (19.7)
PMH
 HTN 90 (100) 76 (100) 1.000
 Diabetes 29 (32.2) 22 (28.9) 0.649
 Hyperlipidemia 24 (26.7) 13 (17.1) 0.140
Initial SBP (mm Hg) in ED 209 ± 23.4 215.8 ± 27.3 0.103
Initial NIHSS score 7.5 (2, 14) 15.5 (6, 25) < 0.001
Initial GCS score 15 (13, 15) 13 (7, 15) < 0.001
ICH score 1 (0, 2) 1.5 (1, 3) < 0.001
Dysphagia/feeding tube placement 26 (28.9) 43 (56.6) < 0.001
Table 2 Cost and outcomes of the study and control groups
Statistically significant values are given in bold
Variables are presented as n (%) in nominal data; mean ± SD or median (IQR) in continuous data
AKI acute kidney disease, DBP diastolic blood pressure, GCS Glasgow coma scale, ICH intracerebral hemorrhage, ICU intensive care unit, IQR interquartile range, LOS 
length of stay, NIHSS National Institutes of Health Stroke Scale, SBP systolic blood pressure
*Multivariate regression models after adjustment for initial SBP, NIHSS, GCS, and ICH scores
Cost and outcomes Study group (n = 90) Control group (n = 76) p value p value*
Duration of nicardipine infusion (h) 55.5 ± 60.1 121.6 ± 141.3 < 0.001 0.002
Nicardipine cost ($) 14,207 (8690, 31,014) 29,299 (14,475, 55,772) < 0.001 0.007
Creatinine levels
 At admission 1.5 ± 1.8 1.2 ± 0.9 0.042 –
 Peak 1.7 ± 2.1 1.5 ± 1.3 0.154 –
 At discharge 1.4 ± 1.6 1.2 ± 1.0 0.108 –
Rate of AKI 19 (21%) 16 (21%) 1.0 0.993
Ventilation support 24 (26.7) 38 (50.0) 0.002 0.986
ICU LOS 2 (1, 5) 5 (3, 10) < 0.001 0.004
Hospital LOS 6 (4, 10) 9 (6, 16) < 0.001 0.125
Favorable outcomes 38 (42.2) 13 (17.1) < 0.001 0.112
Mortality 6 (6.7) 10 (13.2) 0.158 0.789
SBP at discharge 136 ± 16 129 ± 20 0.089 0.068
DBP at discharge 68 ± 13 67 ± 14 0.518 0.671
# of antihypertensives used at discharge 3 (2, 4) 3 (2, 3.5) 0.171 0.804
Cost of hospitalization ($)/patient 24,564 (15,108, 52,646) 47,366 (24,265, 89,843) < 0.001 0.007
Table 2 shows the comparison of nicardipine use, cost, 
and outcomes between the study and control groups. 
In univariate analysis, early initiation of oral antihyper-
tensive agents was associated with significant reduc-
tions in the duration of nicardipine infusion (55.5 ± 60.1 
vs 121.6 ± 141.3  h, p < 0.001), median nicardipine cost 
($14,207 vs $29,299, p < 0.001), ventilation support (26.7% 
vs 50.0%, p = 0.002), LOS in the ICU (median 2 vs 5 days, 
p < 0.001) and hospital (6 vs 9  days, p < 0.001), and total 
cost of hospitalization ($24,564 vs $47,366, p < 0.001). It 
was associated with higher rate of favorable outcomes at 
discharge (42.2% vs 17.1%, p < 0.001). Since rapid blood 
pressure (BP) control may cause higher incidence of 
adverse renal events [13], we compared the creatinine 
levels at admission, peak, and discharge, and rate of acute 
kidney injury (AKI) [18] between the study and control 
groups. Despite significantly higher creatinine level in the 
study group at admission, there was no significant differ-
ence in creatine levels at peak and hospital discharge, and 
rate of AKI between the 2 groups (Table  2). There was 
also no significant difference in SBP, DBP, and median 
numbers of oral antihypertensives that patients were tak-
ing at hospital discharge between the 2 groups. There was 
no hypotensive event in the study group. Only one inci-
dent of hypotension (86/52 mmHg) was observed in the 
control group (1/76, 1.3%).
In stepwise regression analysis of variables indepen-
dently associated with dependent variables, the timing 
of the oral antihypertensive initiation was independently 
associated with duration of nicardipine infusion, nicardi-
pine cost, ICU LOS, and hospital cost. In addition, ini-
tial NIHSS score was also independently associated with 
the duration of nicardipine infusion, hospital and ICU 
LOS, and functional independence, while GCS score was 
predictive of nicardipine and hospital cost. ICH score 
appears to be significantly associated with hospital LOS 
and mortality.
To address the imbalance issue in initial NIHSS, GCS, 
and ICH score between the 2 groups, we performed 
multivariate regression analysis of the data. After adjust-
ing for any potential confounding factors (i.e., initial 
SBP, NIHSS, GCS, and ICH score), early initiation of 
oral antihypertensives was independently associated 
with significant reductions in duration of nicardipine 
infusion (p = 0.002), nicardipine cost (p = 0.007), ICU 
LOS (p = 0.004), and cost of hospitalization (p = 0.007) 
(Table 2). There was no significant difference in require-
ment for ventilation support, functional independence 
(42.2% vs 17.1%, p = 0.112), and mortality (6.7% vs 13.2%, 
p = 0.789) between the 2 groups.
The imbalance in the severity of ICH between the two 
treatment groups likely affected the association between 
the timing of oral antihypertensive administration and 
outcome variables as well as the magnitude of differences 
between the two groups. We therefore performed a sen-
sitivity analysis by dividing patients by admission time 
into control (prior to January 2015) and study (after Janu-
ary 2015) groups. As shown in Table 3, there was no sta-
tistically significant difference in baseline characteristics 
and severity of ICH between the two groups. However, 
the study group showed significantly lower nicardipine 
cost, shorter ICU LOS, and lower cost of hospitalization 
than control group, confirming the benefit of early oral 
antihypertensive protocol.
Discussion
ICH imposes a substantial economic burden on patients 
and society [19]. Although medical complications were 
shown to increase LOS after ICH [20], hypertension was 
found to be the strongest predictor of long hospital stay 
and high cost per visit in patients with ICH [10, 11, 19]. 
Paradoxically, the most effective antihypertensive medi-
cation nicardipine has the highest drug acquisition cost 
[14, 21]. In addition, the need for ICU monitoring during 
IV nicardipine infusion increases ICU LOS, risk of medi-
cal complications, and hospital cost [10, 11, 14, 20].
A previous study with 44 and 35 patients in interven-
tion and control groups, respectively, showed that earlier 
initiation of oral antihypertensive medications reduces 
the duration of nicardipine infusion with substantial 
cost saving [14]. Despite a trend toward reduction, the 
ICU LOS in the intervention group was similar to that 
in the control group possibly due to small sample size. In 
our current study, we have demonstrated that early ini-
tiation of oral antihypertensives has not only decreased 
the duration and cost of nicardipine infusion, but also 
reduced median ICU LOS and cost of hospitalization. 
The decreased ICU LOS in the early oral antihyperten-
sive group is clinically important, as extended ICU LOS 
not only significantly increases the cost of care but also 
the risk of medical complications [20].
There are concerns about adverse effects of early ini-
tiation of oral antihypertensives while on IV nicardi-
pine infusion. One of the concerns is AKI from rapid 
BP reduction and side effects of multiple drugs [22, 23]. 
INTERACT2 and ATACH-2 trials demonstrated that it 
is safe to have rapid lowering of SBP to less than 140 [12, 
13]. There was no significant difference in serious adverse 
events between Intensive-treatment and Standard-treat-
ment groups in the 2 landmark trials. The rate of hypo-
tension was very low in both studies (0.5% vs 0.6% in 
INTERACT2 and 1.2% vs 0.6% in ATACH-2 trial). How-
ever, the rate of renal adverse events within 7 days after 
randomization was significantly higher in the Intensive-
treatment group than in the Standard-treatment group 
(9.0% vs 4.0%, p = 0.002) in the ATACH-2 trial, likely due 
to much lower SBPs (128.9 ± 16) during the first 2  h in 
the Intensive-treatment group [13]. We therefore exam-
ined the renal function between the 2 groups in our 
study. There was no significant difference in the rate of 
AKI between early and late oral antihypertensive groups 
(Table  2). We had excellent BP control at discharge in 
both groups. The rate of hypotension was very low (0% vs 
1.3%), with only 1 incident of hypotension (86/52 mmHg) 
in the control group.
Of note, patients in the study group had less severe ICH 
scores (lower NIHSS and ICH scores and higher GCS 
scores) than the control group. However, after adjust-
ing for NIHSS, GCS, and ICH scores in multivariate 
regression model, multivariate regression models dem-
onstrated that early initiation of oral antihypertensives 
was independently associated with reduced nicardipine 
cost, ICU LOS, and cost of the hospitalization. In addi-
tion, the initial SBP, arguably one of the most important 
factors influencing the duration of nicardipine infusion 
and subsequently ICU LOS and cost, was similar between 
the 2 groups.
However, there was significant selection bias intro-
duced by the “by treatment” group definition. We there-
fore performed a sensitivity analysis by dividing patients 
by admission time into control (prior to January 2015) 
and study (after January 2015) groups. We showed that 
Table 3 Sensitivity analysis of the 2 groups according to the time of admission
Statistically significant values are given in bold
Variables are presented as n (%) in nominal data; mean ± SD or median (IQR) in continuous data
AKI acute kidney disease, ED emergency department, GCS Glasgow coma scale, HTN hypertension, ICH intracerebral hemorrhage, ICU intensive care unit, IQR 
interquartile range, LOS length of stay, NIHSS National Institutes of Health Stroke Scale, PMH past medical history, and SBP systolic blood pressure
Characteristics Study group (n = 126) Control group (n = 40) p value
Age 63.2 ± 15.0 65.0 ± 13.1 0.508
Male 64 (50.8) 22 (55.0) 0.643
Race 0.755
 White 48 (38.1) 17 (42.5)
 Hispanic 41 (32.5) 15 (37.5)
 African‑American 8 (6.3) 2 (5.0)
 Asian 29 (23.0) 6 (15.0)
PMH
 HTN 126 (100) 40 (100) 1.000
 Diabetes 39 (31.0) 12 (30.0) 0.909
 Hyperlipidemia 31 (24.6) 6 (15.0) 0.276
Initial SBP (mm Hg) in ED 211.7 ± 23.8 215.2 ± 25.7 0.449
Initial NIHSS score 8.5 (2, 18) 10 (4, 21) 0.338
Initial GCS score 15 (12, 15) 15 (11, 15) 0.948
ICH score 1 (0, 2) 1 (0, 2) 0.534
Dysphagia/Feeding tube placement 49 (38.9) 20 (50.0) 0.214
Duration of nicardipine infusion (h) 71.6 ± 102.0 130.5 ± 123.5 0.003
Nicardipine cost ($) 17,080 (9413, 35,850) 29,009 (13,924, 56,237) 0.006
Creatinine levels
 At admission 1.4 ± 1.6 1.3 ± 0.9 0.812
 Peak 1.6 ± 1.9 1.7 ± 1.4 0.821
 At discharge 1.3 ± 1.4 1.4 ± 1.2 0.898
Rate of AKI 28 (22.2) 7 (17.5) 0.524
Ventilation support 44 (34.9) 18 (45.0) 0.251
ICU LOS 2 (2, 5) 5 (3, 10) 0.003
Hospital LOS 7 (4, 12) 10 (5, 16) 0.066
Favorable outcomes 44 (34.9) 7 (17.5) 0.037
Mortality 12 (9.5) 4 (10.0) 1.000
SBP at discharge 132.5 ± 17.8 136.0 ± 19.4 0.317
# of antihypertensives used at discharge 3 (2, 4) 3 (2, 3) 0.580
Cost of hospitalization ($)/patient 28,508 (16,271, 59,952) 47,269 (22,433, 91,774) 0.013
“by time” group definition was able to eliminate the 
imbalance in severity of ICH between the two groups 
and the significant effect of the early administration of 
oral antihypertensives on cost and ICU length of stay was 
maintained in the multivariate model (Table 3).
Our study has a few limitations. First, it is a single-
center retrospective study. Second, only patients with 
initial SBP > 180  mmHg were included. Our results may 
only apply to patients with severe hypertension (i.e., 
SBP > 180 mmHg). Third, our sample sizes were relatively 
small and likely underpowered to identify all potential 
confounding factors. We also do not have 90-day out-
come data. Further studies with long-term follow-up are 
warranted to investigate the financial impact and long-
term outcome benefit of early oral antihypertensives. 
Lastly, our study and control groups were substantially 
imbalanced in terms of severity of illness. Although the 
multivariate models demonstrate independent asso-
ciation of early initiation of oral antihypertensives with 
reduced nicardipine cost, ICU LOS, and cost of hospitali-
zation, the true magnitude of this difference was smaller 
per “by time” group assignment sensitivity analysis. The 
cost-effectiveness of early oral antihypertensives needs to 
be further investigated with well-designed randomized 
control trial.
Conclusion
In summary, early initiation of oral antihypertensives 
may significantly reduce nicardipine infusion, ICU LOS 
and total cost of hospitalization. Our study demonstrates 
significant financial impact of early initiation of oral anti-
hypertensives in patients with hypertensive ICH that is 
safe and independent of baseline clinical characteristics.
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